Atazanavir’s Effects on CV Risks in HIV Infected Veterans

by U.S. Medicine

December 15, 2017

SALT LAKE CITY—Patients with HIV infection have an increased risk of cardiovascular disease compared with uninfected individuals. Oftentimes, they receive antiretroviral therapy with atazanavir (ATV), which delays progression of atherosclerosis markers.

Whether the treatment also reduces cardiovascular disease event risk compared with other antiretroviral regimens is unknown, however, according to a study in the journal AIDS.1

Researchers from the Salt Lake City VAMC and other institutions conducted a population-based, noninterventional, historical cohort study conducted from July 1, 2003, through Dec. 31, 2015, to better understand the effects. The focus was on 9,500 treatment-naïve HIV-infected patients at VHA hospitals and clinics through the United States. Participants were initiating antiretroviral regimens containing ATV, other protease inhibitors, nonnucleoside reverse transcriptase inhibitors (NNRTIs) or integrase strand transfer inhibitors (INSTIs).

The study team analyzed incidence rates of myocardial infarction (MI), stroke and all-cause mortality within each regimen: ATV vs. other protease inhibitor, NNRTI, or INSTI.

Results indicated that incidence rates for MI, stroke and all-cause mortality with ATV-containing regimens (5.2, 10.4, and 16.0 per 1,000 patient-years, respectively) were lower than with regimens containing other protease inhibitors (10.2, 21.9, and 23.3 per 1,000 patient-years), NNRTIs (7.5, 15.9, and 17.5 per 1,000 patient-years) or INSTIs (13.0, 33.1, and 21.5 per 1,000 patient-years). 

After inverse probability of treatment-weighting, adjusted hazard ratios for MI, stroke and all-cause mortality with ATV-containing regimens vs. all non-ATV-containing regimens were 0.59 (0.41-0.84), 0.64 (0.50-0.81), and 0.90 (0.73-1.11), respectively.

“Among treatment-naive HIV-infected patients in the Veterans Health Administration initiating ATV-containing regimens, risk of both MI and stroke were significantly lower than in those initiating regimens containing other protease inhibitors, NNRTIs or INSTIs,” researchers concluded.

  1. LaFleur J, Bress AP, Rosenblatt L, Crook J, Sax PE, Myers J, Ritchings C. Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. AIDS. 2017 Sep 24;31(15):2095-2106. doi: 10.1097/QAD.0000000000001594. PubMed PMID: 28692532; PubMed Central PMCID: PMC5603981.

Related Articles

VA’s Effort to Expand Telemedicine Across All States Moves Forward

The House voted in favor of a bill giving VA authority to allow its licensed healthcare providers to practice telemedicine in any state, regardless of whether the patient or provider is located on federal government property.

VA Clinicians Might Be Switching Rheumatoid Arthritis Patients to Biologics Too Quickly

The development of multiple biologic agents for the treatment of rheumatoid arthritis (RA) in recent years has given patients and clinicians more options for therapy.

U.S. Medicine Recommends

More From hiv


HIV Infection Linked to 40% Increase in Veterans’ Risk of Developing Heart Failure

Antiretroviral therapy has extended the lives of veterans with human immunodeficiency virus (HIV) by decades, but a new threat could cut back their longevity.


Infectious Disease Specialist Uses Telehealth for Rural Veterans With HIV

Veterans living in rural areas face a lot of challenges, the most common of which is having to travel long distances to access VA medical care.


Targeting Lung Cancer Prevention to Veterans With HIV

New veteran research is being touted as a way to better target lung-cancer prevention measures to high-risk groups.


Veterans with HIV Responsive to Standard Diabetes Therapy

With Type 2 diabetes increasingly common in HIV-infected individuals, are standard oral diabetes medications as effective in that population?


COPD Associated With Frailty in HIV-Infected Veterans

With chronic obstructive pulmonary disease (COPD) prevalence increasing among aging HIV-infected patients, a recent study sought to determine how that relates to frailty in veterans treated at the VA.

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up